Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 34

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 34
---
0 to September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all financial, legal, and operational aspects of the business from April 2019 to September 2020. From 2011 to February 2019, Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law firm, where Mr. Elder’s practice focused primarily on counseling public companies on capital markets transactions, mergers and acquisitions, and corporate governance matters. Prior to joining Dechert LLP, Mr. Elder served as an analyst for Creative Financial Group. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.

Kelly Blackburn, M.H.A., has served as Executive Vice President, Clinical Development of the Company since April 2025 and previously served as Senior Vice President, Clinical Development, from August 2023 to April 2025. Ms. Blackburn also previously served as Senior Vice President, Clinical Development of EIP from May 2018 to August 2023. Prior to joining EIP, Ms. Blackburn served as Vice President, Clinical Affairs of aTyr Pharma, Inc. (NASDAQ: LIFE) from July 2013 to July 2016. Ms. Blackburn served as a clinical development consultant from September 2012 to July 2013 to a number of companies, including Agios Pharmaceuticals, Promedior Inc. and aTyr Pharma, Inc. Prior to this, Ms. Blackburn was the Vice President, Clinical Development Operations at Vertex Pharmaceuticals (NASDAQ: VRTX), a global biotechnology company, from September 2006 to September 2012 overseeing programs for Incivek and Kalydeco, as well as their early development programs. From September 2002 to August 2006, Ms. Blackburn was Director of Clinical and Safety Operations for Millennium Pharmaceuticals where she was responsible for the VELCADE program which was successfully approved during her tenure. Ms. Blackburn holds a B.S. in biochemistry from University of New Hampshire, an M.H.A. from Quinnipiac College and a M.Ed. from Cambridge College.

Mark De Rosch, Ph.D., FRAPS, has been appointed as the Company’s Executive Vice President, Regulatory and Government Affairs and Program Management, effective May 1,